Want to see INBX full AI Analyst Report?

Inhibrx Biosciences Inc (INBX) Price & Analysis

117 Followers

INBX Stock Chart & Stats

$122.72

$2.17(2.66%)

At close: Jul 27 4:00 PM EDT

$122.72

$2.17(2.66%)

Day’s Range― - ―

52-Week Range$28.16 - $155.29

Previous CloseN/A

Volume61.50K

Average Volume (3M)306.31K

Market Cap

$1.45B

Enterprise Value$1.53B

Total Cash (Recent Filing)$133.34M

Total Debt (Recent Filing)$5.34M

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Nov 13, 2026

EPS Estimate

-2.45

Next Dividend Ex-DateN/A

Dividend Yield5.23%

Share Statistics

EPS (TTM)-8.88

Shares Outstanding14,717,660

10 Day Avg. Volume195,078

30 Day Avg. Volume306,312

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)153.07

Price to Sales (P/S)941.13

P/FCF Ratio-9.42

Enterprise Value/Market Cap1.06

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-910.83

Enterprise Value/Ebitda-12.73

Forecast

1Y Price Target

$266.67

Price Target Upside117.30% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-9.41

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Phase 2 Clinical ValidationThe Phase 2 combination results provide clinically meaningful validation for INBRX-106, with response and interim progression-free-survival advantages over pembrolizumab alone. If confirmed in expansion and Phase 3, this signal could support future adoption and expand the company’s strategic options.

Pipeline ExpansionThe updated presentation identifies multiple development paths for INBRX-106, including Phase 3 planning, perioperative lung cancer work and vaccine combinations, while also highlighting ozekibart. This breadth can diversify clinical upside and create several milestone opportunities.

Cash ResourcesReported cash and cash equivalents of $219.5 million give the company a material funding resource for advancing trials and reaching stated milestones. Although cash will be consumed by development, this liquidity can support execution across the pipeline over the medium term.

Bears Say

Absent Recurring RevenueThe lack of recurring product revenue leaves the company dependent on future clinical success, collaborations or financing rather than an established commercial engine. Large operating and net losses also show that the pipeline currently lacks earnings support and remains fundamentally unprofitable.

Persistent Cash BurnPersistent operating and free-cash-flow losses mean ongoing research and clinical development are not self-funded. Continued cash consumption can shorten the period supported by existing resources and increase reliance on external capital, creating dilution or financing risk as programs advance.

Negative Equity And Leverage VolatilityNegative stockholders’ equity reduces financial flexibility and leaves less balance-sheet support for future obligations. The sharp history of leverage changes also indicates an unstable capital structure, which may complicate refinancing and increase dependence on equity or debt financing.

Inhibrx Biosciences Inc News

Insiders Load Up on These 2 ‘Strong Buy’ Stocks — Should You Follow Their Footsteps?

Investors are always seeking some new sign, some signal that will indicate the right stock, and the right...

1d ago

APLD

INBX

Inhibrx CEO buys $998.8K in common stock as part of option exercise

In a regulatory filing, Inhibrx (INBX) disclosed that its CEO Mark Lappe bought 10K shares of common stock...

24d ago

INBX

Closing Bell Movers: Stitch Fix down 18% after results and guidance

U.N. General Assembly standoff pitting President Trump’s threat to annihilate Iran against a defiant tone from Iranian President...

29d ago

FUL

Inhibrx director buys $500K in common stock

In a regulatory filing, Inhibrx (INBX) disclosed that its director Jon Kayyem bought 5K shares of common stock...

29d ago

INBX

Inhibrx Biosciences Updates Investor Presentation and Pipeline Outlook

Inhibrx Biosciences Inc ( ($INBX) ) has issued an update. On September 28, 2026, Inhibrx Biosciences posted an...

24d ago

INBX

Inhibrx Biosciences reports strong Phase 2 INBRX-106 data

Inhibrx Biosciences Inc ( ($INBX) ) has provided an announcement. On September 8, 2026, Inhibrx Biosciences reported primary...

1M ago

INBX

Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study

Inhibrx (INBX) Biosciences announced the primary endpoint results from the randomized and controlled Phase 2 portion of the...

1M ago

INBX

Inhibrx initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Inhibrx (INBX) with a Buy rating and $245 price target Inhibrx is a...

2M ago

INBX

Inhibrx reports Q2 EPS ($2.34), consensus ($1.85)

Reports Q2 revenue $0 vs. $1.3M last year. As of June 30, the company had cash and cash...

2M ago

INBX

Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained

In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Inhibrx Biosciences Inc,...

2M ago

INBX

Inhibrx Biosciences Expands Credit Facility to $500 Million

Inhibrx Biosciences Inc ( ($INBX) ) just unveiled an announcement. On July 15, 2026, Inhibrx Biosciences Inc. amended...

3M ago

INBX

Citizens healthcare analysts hold an analyst/industry conference call

Healthcare Analysts discuss understanding the developing landscape in Colorectal Cancer (CRC) (relevant companies BCAX, CTMX, EXEL, INBX, INCY,...

4M ago

CTMX

EXEL

Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy

The latest announcement is out from Inhibrx Biosciences Inc ( ($INBX) ). On June 15, 2026, Inhibrx Biosciences...

4M ago

INBX

Inhibrx announces FDA acceptance of BLA for ozekibart

Inhibrx (INBX) Biosciences announced that the U.S. FDA has accepted for filing its Biologics License Application seeking approval...

4M ago

INBX

INBX FAQ

What was Inhibrx Biosciences Inc’s price range in the past 12 months?

Inhibrx Biosciences Inc lowest stock price was $28.16 and its highest was $155.29 in the past 12 months.

What is Inhibrx Biosciences Inc’s market cap?

Inhibrx Biosciences Inc’s market cap is $1.45B.

When is Inhibrx Biosciences Inc’s upcoming earnings report date?

Inhibrx Biosciences Inc’s upcoming earnings report date is Nov 13, 2026 which is in 22 days.

How were Inhibrx Biosciences Inc’s earnings last quarter?

Inhibrx Biosciences Inc released its earnings results on Aug 13, 2026. The company reported -$2.34 earnings per share for the quarter, missing the consensus estimate of -$2.28 by -$0.06.

Is Inhibrx Biosciences Inc overvalued?

According to Wall Street analysts Inhibrx Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Inhibrx Biosciences Inc pay dividends?

Inhibrx Biosciences Inc pays a Notavailable dividend of $0.85 which represents an annual dividend yield of 5.23%. See more information on Inhibrx Biosciences Inc dividends here

What is Inhibrx Biosciences Inc’s EPS estimate?

Inhibrx Biosciences Inc’s EPS estimate is -2.45.

How many shares outstanding does Inhibrx Biosciences Inc have?

Inhibrx Biosciences Inc has 14,717,660 shares outstanding.

What happened to Inhibrx Biosciences Inc’s price movement after its last earnings report?

Inhibrx Biosciences Inc reported an EPS of -$2.34 in its last earnings report, missing expectations of -$2.28. Following the earnings report the stock price went down -8.906%.

Which hedge fund is a major shareholder of Inhibrx Biosciences Inc?

Currently, no hedge funds are holding shares in INBX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Inhibrx Biosciences Inc Stock Smart Score

Outperform

Fundamentals

Return on Equity

1893.60%

Trailing 12-Months

Asset Growth

-27.29%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Inhibrx Biosciences Inc

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc (INBX) Earnings & Revenues

Historic Earnings Reports

INBX Stock 12 Month Forecast

Average Price Target

$266.67

▲(117.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","179":"$179","326":"$326","105.5":"$105.5","252.5":"$252.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$325.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":266.6666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$266.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$230.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,105.5,179,252.5,326],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.93,115.39692307692309,132.86384615384617,150.33076923076925,167.79769230769233,185.2646153846154,202.73153846153846,220.19846153846154,237.66538461538462,255.1323076923077,272.59923076923076,290.06615384615384,307.5330769230769,{"y":325,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.93,110.9097435897436,123.88948717948719,136.86923076923077,149.84897435897437,162.82871794871795,175.80846153846153,188.78820512820513,201.76794871794874,214.74769230769232,227.7274358974359,240.7071794871795,253.68692307692308,{"y":266.6666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.93,108.08923076923078,118.24846153846154,128.40769230769232,138.56692307692308,148.72615384615386,158.88538461538462,169.04461538461538,179.20384615384614,189.36307692307693,199.5223076923077,209.68153846153848,219.84076923076924,{"y":230,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.98,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":81.66,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":80.77,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":79,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":82.23,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":77.49,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":67.05,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.79,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.29,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.05,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.66,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.93,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >